Hong Kong is emerging as a strategic hub for life sciences innovation in Greater China, according to industry analysts and government reports. The city’s unique position as a gateway between mainland China and global markets, combined with recent investments in research infrastructure, has accelerated its biotech sector growth.
Over the past five years, Hong Kong has seen a 40% increase in life sciences startups, with particular strengths in precision medicine and AI-driven drug discovery. The government’s HK$10 billion (US$1.28 billion) investment in the Hong Kong-Shenzhen Innovation and Technology Park has created new opportunities for cross-border collaboration.
“Hong Kong offers what mainland cities often lack – strong IP protections, international talent networks, and access to global capital markets,” said a biotechnology analyst at a major investment bank who requested anonymity due to company policy. However, some researchers note that high operating costs and limited manufacturing capacity could constrain long-term growth.
The city recently hosted its first international biotech summit, attracting over 3,000 participants from 25 countries. This comes as Chinese pharmaceutical companies increasingly use Hong Kong as a testing ground for international expansion strategies.